Aim. To evaluate the influence of Prestarium A (perindopril as orally dispersing pills, “Les Laboratories Servier”, France) on dynamics of systolic and diastolic arterial pressure and life quality parameters in patients with mild to moderate arterial hypertension.Material and methods. A 12-week prospective observation was performed on 13 women and 9 men in the age of 38 to 60 (mean age 49 y. o.) with mild and moderate arterial hypertension, who received Prestarium A as antihypertensive treatment with the mean daily dose 8,4±2,3 mg. The main endpoints were: 1) changes in mean office blood pressure and of the life quality by EQ-5Q and SF-36 questionnaires at the final visit; 2) intolerability of the drug.Results. In 12 weeks of Prestarium A therapy mean blood pressure significantly decreased from baseline 159,6±12,3 и 101,2±4,3 mmHg to 133,7±7,8 и 83,5±6,2 mmHg (р=0,0009 и р=0,0011, resp., for systolic and diastolic blood pressure; Wilkokson criteria). Target blood pressure (<140 and 90 mmHg) was achieved in 4 weeks in 13 (59%), in 8 weeks in 17 (77%), and in 12 weeks in 20 (86%) patients, and there were no any side effects. Monotherapy by Prestarium A was followed by significant improvement of life quality of the patients according to analogue scale (EQ-5D) from 60,3±6,8 to 75,4±7,3 points (р=0,0041; Wilkockson criteria) and by the scale of physical functioning SF-36 from 48,6±7,6 to 61,6±5,8 points (р=0,0001; Wilkokson criteria).Conclusion. Therapy with Prestarium A in patients with non-complicated mild and moderate arterial hypertension during 12 weeks with average dosage 8,4±2,3 mg made it to achieve target blood pressure levels in 86% patients. Relevant decrease of arterial pressure, achieved by the last visit, was followed by an improvement of lfe quality of the patients, and the therapy itself was perfectly tolerated.
1. Recommendations for treatment of hypertension ESH/ESC 2013. Russ J Cardiol 2014, 1 (105): 7-94. Russian (Рекомендации по лечению артериальной гипертонии ESH/ESC 2013. Российский кардиологический журнал 2014, 1 (105): 7-94).
2. Shalnova SA et al. Arterial hypertension and assessment of total cardiovascular risk: results from the epidemiological monitoring of hypertension. Consilium Medicum 2007; 9(11): 31-4. Russian (Шальнова С. А. и др. Артериальная гипертония и оценка суммарного сердечно-сосудистого риска: результаты эпидемиологического мониторинга гипертонии. Consilium Medicum. 2007; 9(11): 31-4).
3. Shalnova SA et al. Arterial hypertension: prevalence, awareness, taking antihypertensive drugs and the effectiveness of treatment among the population of the Russian Federation. Russ J Cardiol 2006; 4: 45--50. Russian (Шальнова С. А. и др. Артериальная гипертония: распространённость, осведомленность, приём антигипертензивных препаратов и эффективность лечения среди населения Российской Федерации. Российский кардиологический журнал 2006; 4: 45-50).
4. Kobalava JD, Kotovskaya YuV. Arterial hypertension: keys to diagnosis and treatment. M. 2007, 432 p. Russian (Кобалава Ж. Д., Котовская Ю. В. Артериальная гипертония: ключи к диагностике и лечению. М. 2007. 432 с).
5. Effects of ACE inhibitors, calcium antagonists, and other blood pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000; 355: 1955-64.
6. Savarese G, et al., A Meta-Analysis Reporting Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients Without Heart Failure. J Am Coll Cardiol. 2013; 61(2): 131-42.
7. Elliott WJ, Meyer PM. Effects of perindopril on cardiovascular outcomes in hypertension clinical trials: traditional and network meta-analyses. Journal of the American Society of Hypertension April 2014; 8, 4, Suppl.: e69.
8. Simoons ML Angiotensin-converting enzyme inhibition by perindopril in cardiovascular disease. European Heart Journal Supplements (2009) 11 (Supplement E), E4-E8.
9. Konradi AO, Polunicheva EV. Lack of adherence to treatment of hypertension: causes and methods of correction. Hypertension 2004; 10, 3: 137-43. Russian (Конради А. О., Полуничева Е. В. Недостаточная приверженность к лечению артериальной гипертензии: причины и пути коррекции. Артериальная гипертензия 2004; 10, 3: 137-43).
10. Sabate E. Adherence to long-term therapies: evidence for action. E. Sabate. Geneva: WHO, 2003.
11. Osterberg L. Adherence to Medication. N. Engl. J. Med. 2005; 353: 487-97.
12. Indukaeva EV, Ogarkov MY. Medico-social aspects of adherence to treatment of hypertension 2012: 34-8. Russian (Индукаева Е. В., Огарков М. Ю. Медико-социальные аспекты приверженности лечения артериальной гипертонии 2012: 34-8).
13. Novik AA, Ionova TI. Guide to the study of quality of life in medicine. 2nd edition. Ed. by Acad. The RAMS Y. L. Shevchenko. M. 2007. p. 320. Russian (Новик А. А., Ионова Т. И. Руководство по исследованию качества жизни в медицине. 2-е издание. Под ред. Акад. РАМН Ю. Л. Шевченко. М. 2007.320 с).
14. Brooks R (1996). EuroQol: the current state of play. Health Policy 37(1):53-72.
15. Ware JE, Kosinski M, Keller SD. SF-36 Physical and mental Health Summary Scales: A Users Manual// The Health Institute, New England Medical Center. Boston, Mass. 1994.
16. The EuroQol Group (1990). EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 16(3): 199-208.
17. Rebrova OY. Statistical analysis of medical data. The use of the software package STATISTICA. M: Media Sphere 2002; 312c. Russian (Реброва О. Ю. Статистический анализ медицинских данных. Применение пакета прикладных программ STATISTICA. О. Ю. Реброва. М.: Медиа Сфера. 2002. 312 c).
